Loading…
Tibetan medicine maker best known for herbal plaster patches used to treat joint and muscle pain.
Tibetan medicine maker best known for herbal plaster patches used to treat joint and muscle pain.
In one line: A Chinese Tibetan-medicine Salonpas maker.
Moat: narrow (brand, IP / patents). Distinctive Tibetan-medicine brand and formula recipes not easily replicated by mainstream TCM makers.
Headquarters: Lhasa, Tibet, China · Employees: 3,203
Size Tibet Cheezheng Tibetan Medicine (002287.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $1.66B, the 1492nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.37 on 6 Nov 2026.
Performance Over six months the shares fell 14.8%, against -2.5% for the median peer and -16.4% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue fell 6.5% over the last twelve months (peer median +11.8%); the operating margin is 27.6% (peer median 14.8%).
Valuation It trades at 4.2× enterprise value to sales against a peer median of 3.3× (6th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.0 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.23B | CN¥2.39B | CN¥2.31B | CN¥2.02B | CN¥2.02B |
| Revenue growth | — | +3% | +14% | 0% | — |
| Gross profit | CN¥1.90B | CN¥1.92B | CN¥1.84B | CN¥1.64B | CN¥1.64B |
| EBITDA | n/a | CN¥744M | CN¥675M | CN¥562M | CN¥611M |
| Net income | CN¥632M | CN¥648M | CN¥582M | CN¥581M | CN¥473M |
| Free cash flow | CN¥353M | CN¥651M | CN¥273M | CN¥737M | CN¥43.8M |
| Capital expenditure | CN¥147M | CN¥153M | CN¥255M | CN¥235M | CN¥272M |
| Total debt | CN¥935M | CN¥1.02B | CN¥1.76B | CN¥1.55B | CN¥1.74B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine 002287.SZ | $1.66B | -15% | -7% | 28% | 4.2× | -1.1% |
| Henan Lingrui Pharmaceutial 600285.SS | $2.02B | +7% | +5% | 22% | 3.2× | -4.8% |
| Shandong Buchang Pharmaceuticals 603858.SS | $2.31B | -7% | +4% | 10% | 1.5× | -2.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002287.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.2% | +0.5% | 10th lowest of 21 |
| 6-month return | -14.8% | -2.5% | 6th lowest of 21 |
| Distance from 52-week high | -27.1% | -19.5% | 8th lowest of 21 |
| Revenue growth (TTM) | -6.5% | +11.8% | 3rd lowest of 21 |
| Operating margin | 27.6% | 14.8% | 4th highest of 20 |
| EV / Sales | 4.2× | 3.3× | 6th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | -1.1% | 1.5% | 7th least demanding of 17 |
| Growth delivered (Del g) | +10.4% | +8.8% | 9th highest of 17 |
| Hurdle (Req g minus delivered) | -11.5 pp | -8.4 pp | 7th least demanding of 17 |
| ROIC minus cost of capital | +10.0 pp | +2.7 pp | 6th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | 4.2× | -1.1% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 1.0× | -6.7% | +3.9% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 3.4× | 4.5% | +60.2% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 4.4× | -2.2% | +5.5% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | 3.6× | 5.3% | +10.4% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 18.9× | n/a | n/a |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | 0.6× | -0.8% | -2.1% |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 2.7× | 11.0% | +15.3% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 1.3× | -3.0% | +4.4% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 3.3× | 2.1% | +26.7% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 3.3× | 23.5% | +10.6% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 4.4× | 11.4% | -3.9% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 7.2× | 0.9% | +15.5% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 3.9× | -2.5% | +11.6% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 5.1× | 14.1% | +62.3% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.50B | -10% | -1% | 13% | 1.6× | -8.3% | +5.3% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 1.0× | -2.0% | +7.1% |
| By-health 300146.SZ | China | $2.61B | -1% | +10% | 11% | 2.0× | 5.1% | +0.6% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | n/a | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 3.0× | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 2.3× | n/a | n/a |